Quercetin as a Potential Modulator of P-Glycoprotein Expression and Function in Cells of Human Pancreatic Carcinoma Line Resistant to Daunorubicin

Sylwia Borska 1,*, Miroslaw Sopel 1, Magdalena Chmielewska 1, Maciej Zabel 1,2 and Piotr Dziegiel 1,2,3

1 Department of Histology and Embryology, Medical University, T. Chalubinski Street 6a, 50-368 Wroclaw, Poland
2 Department of Histology and Embryology, University of Medical Sciences in Poznan, Swiecieckiego Street 6, 60-781 Poznan, Poland
3 Lower Silesian Centre of Oncology, Hirszfeld Square 12, 53-413 Wroclaw, Poland

* Author to whom correspondence should be addressed; E-Mail: borska@hist.am.wroc.pl; Tel.: +48 0717841683; Fax: +48 0717840082.

Received: 29 December 2009; in revised form: 28 January 2010 / Accepted: 3 February 2010 / Published: 9 February 2010

Abstract: P-glycoprotein (P-gp) is one of the ABC transporters responsible for the resistance of several tumours to successful chemotherapy. Numerous agents are capable of interfering with the P-gp-mediated export of drugs but unfortunately most of them produce serious side effects. Some plant polyphenols, including the flavonol quercetin (Q), manifest anti-neoplastic activity mainly due to their influence on cell cycle control and apoptosis. Reports are also available which show that Q may intensify action of cytostatic drugs and suppress the multidrug resistance (MDR) phenomenon. The study aimed at determination if Q sensitizes cells resistant to daunorubicin (DB) through its effect on P-gp expression and action. The experiments were conducted on two cell lines of human pancreatic carcinoma, resistant to DB EPP85-181RDB and sensitive EPP85-181P as a comparison. Cells of both lines were exposed to selected concentrations of Q and DB, and then membranous expression of P-gp and its transport function were examined. The influence on expression of gene for P-gp (ABCB1) was also investigated. Results of the studies confirmed that Q affects expression and function of P-gp in a concentration-dependent manner. Moreover it decreased expression of ABCB1. Thus, Q may be considered as a potential modulator of P-gp.
Introduction

The phenomenon of multidrug resistance (MDR) was described for the first time by Kessel et al. in 1968. At present, insensitivity of neoplastic cells to chemotherapeutic agents is thought to represent one of the main causes of failure in treatment of tumour diseases. The best recognised and the most frequent cause of the resistance involves an increased activity of ATP-binding cassette family transporters (ABC) and is called ‘classical’ MDR [1]. Among membrane transporters, the overexpression most frequently involves P-glycoprotein (P-gp), encoded by the \textit{ABCB1} gene, and has been closely associated with unfavourable prognostic index in cases of several types of tumours [2–4].

The substrates for P-gp represent substances of a variable structure, chemical properties and mechanisms of action [5]. Drugs affected by the MDR phenotype include several cytostatic drugs e.g., anthracyclines [6]. Daunorubicin (DB) which belongs to that group manifests a multi-directional mode of action. Its best characterized activities include an effect on activity of topoisomerase II (topo II) and interactions with DNA through formation of intercalation complexes, covalent bonds and modification of nucleic acid bases. This leads to disturbances in processes such as replication, transcription, DNA repair and most frequently results in cell apoptosis. Its involvement in generation of reactive oxygen species and lipid peroxidation has been also well documented [6–8]. Similarly to cases of other anti-neoplastic drugs, clinical application of DB is restricted due to its cytotoxic effects on normal cells. Within a year following termination of treatment with anthracyclines, the patients used to demonstrate cardiomyopathy and chronic cardiac failure. A bone marrow suppression and thrombosis were also described. In frequent cases MDR is developed often correlated with increased P-gp expression [8,9].

A large number of compounds have been identified that are capable of overruling MDR by interfering with the P-gp-mediated export of the drugs used for treatment. A search for P-gp modulators which would selectively inhibit activity of that transporter without any negative side effects has been continued [10,11]. Extensive hopes are linked to application of some plant polyphenols e.g., quercetin (Q). Flavonol Q (structure is shown in Figure 1) belongs to the large group of flavonoids, manifested in numerous edible plants. For several decades Q has been documented as a strong antioxidant, anti-inflammatory and vasodilating agent, decreasing blood pressure and inhibiting aggregation of blood platelets. Many data showed that Q might exert inhibitory effects on all stages of carcinogenesis [12–15]. Antineoplastic properties of Q are linked, first of all, to its effect on expression of some genes engaged in cell cycle control. Q exerts also a direct effect on activity of various type protein kinases significant in the process of carcinogenesis and the associated with them metabolic pathways [16–20]. Apart from its effect on induction of apoptosis in neoplastic cells, Q is considered to be effective in restoring drug sensitivity of MDR tumour cells. The results of \textit{in vivo} and \textit{in vitro} studies seem promising [21–24].

\textbf{Keywords:} quercetin; daunorubicin; P-glycoprotein; multidrug resistance
This study aimed at determination whether Q sensitizes cells of pancreatic carcinoma resistant cell line to action of DB by decreasing membraneous expression of P-gp, blocking its transport functions and affecting expression of \textit{ABCB1} gene.

\textbf{Results and Discussion}

In our study two human pancreatic cancer cell lines, a resistant (RDB) and a sensitive (P) to DB, provided the cell models. We investigated the effects of Q against P-gp overexpression in cells with RDB phenotype and the comparison with P line as a control.

Cytotoxicity tests have demonstrated that Q inhibits cell divisions in both neoplastic cell lines in the concentration-related manner (Tables 1, 2). Also the resistance factor (RF) for Q has approached 1 (RF = 1.25), which points to the lack of resistance to the compound. After 72 h of Q action IC$_{50}$ for P cell line was estimated at 8 µM. In the case of RDB line IC$_{50}$ amounted to 12 µM. For further experiments Q concentrations of 3, 6 and 12 µM were selected.

\textbf{Table 1.} Cytotoxic effect of Q on cells in DB-sensitive line as related to concentration of the drug after 72 h; \( p < 0.001 \) for optical density (OD) of C vs. all. C—Control.

\begin{center}
\begin{tabular}{|c|c|c|c|c|c|c|c|c|}
\hline
Q concentration [µM] & C (0) & 1 & 2 & 3 & 6 & 12 & 25 & 50 \\
\hline
OD & 2.472 & 2.363 & 2.175 & 1.930 & 1.596 & 0.650 & 0.351 & 0.273 \\
SD & 0.024 & 0.033 & 0.033 & 0.033 & 0.048 & 0.030 & 0.030 & 0.030 \\
% of C value & 100 & 95.584 & 87.999 & 78.074 & 64.556 & 26.281 & 14.186 & 11.057 \\
\hline
\end{tabular}
\end{center}

\textbf{Table 2.} Cytotoxic effect of Q on cells of DB-resistant line, as related to drug concentration after 72h; \( p < 0.001 \) for optical density (OD) of C vs. all. C—Control.

\begin{center}
\begin{tabular}{|c|c|c|c|c|c|c|c|c|}
\hline
Q [µM] & C (0) & 1 & 2 & 3 & 6 & 12 & 25 & 50 \\
\hline
OD & 2.363 & 2.317 & 2.277 & 2.254 & 1.809 & 1.192 & 1.022 & 0.649 \\
SD & 0.035 & 0.119 & 0.021 & 0.059 & 0.013 & 0.008 & 0.058 & 0.039 \\
% of C value & 100 & 98.053 & 96.360 & 95.380 & 76.552 & 50.444 & 43.235 & 27.483 \\
\hline
\end{tabular}
\end{center}

Many data show that Q manifests antiproliferative and pro-apoptotic properties, as documented in cases of multiple types of tumours. Additionally, results of studies suggest that Q may act
synergistically with other anticancer substances and that it may sensitize some neoplastic cells to the apoptotic effect of cytostatic drugs [25–27]. Antiproliferative effect of Q on both pancreatic cell lines, augmentation of DB cytotoxic action in P cells and overcoming DB-resistance in RDB cells were proved in our studies.

The effect of Q on P-gp examined using immunocychemistry and Western blotting analysis proved that Q affects the protein expression level. Immunocytochemical staining demonstrated that in the P line of pancreatic carcinoma no P-gp could be detected in cell membranes, probably due to very low expression of that protein. In the case of RDB cell line the immunostaining showed presence of P-gp in cell membranes in almost 100% of cells. As compared to the control, a statistically significant decrease in the expression could be observed only after treatment with Q12, Q12/K1 (see Figure 2) and Q12/K2, and amounted to 20%, 22% and 23% respectively. However, the differences between Q12, Q12/K1 and Q12/K2 were insignificant (p > 0.05).

**Figure 2.** Expression of P-gp in membranes of cells in EPG85-257RDB line, subjected to action of Q12/K1. ×200.

Western blot analyses confirmed tendency shown in the immunocytochemical stainings. After 72 h treatment of Q12 the amount of P-gp decreased in RDB cells of 30% (Figure 3).

**Figure 3.** Western blotting analysis of P-gp expression after treatment with Q12 in RDB line. C219 detected 170kDa band in RDB line (lanes 2-5), revealing the decrease in P-gp expression level in RDB cell lines incubated with Q12 (lanes 4, 5). P cells (lane 1) were used as negative control for P-gp, and actin (42kDa) staining was used as loading control.
Since P-gp expression level not always correlates with efficacy of drugs elimination from the cells, a functional test was also performed, evaluating P-gp transport function basing on measurement of calcein AM accumulation (CAM). The test with CAM is commonly applied in studies of this type and it is regarded to be effective [11,21,28]. CAM retention coefficient after administration of DB alone manifested no significant alterations in CAM retention, as compared to the control. We have demonstrated that Q12 decreased significantly P-gp transport functions in the RDB cells (Figure 4). A decrease of calcein retention (16%) was noted also following application of Q6, even if membranous expression of P-gp did not decrease significantly in this case.

**Figure 4.** Retention of calcein in cells of EPP85-181RDB line following administration of various Q concentrations, as compared to the control; * p < 0.001 as compared to control.

![Figure 4](image)

**Figure 5.** Retention of calcein in cells of EPP85-181RDB line following administration of Q and DB combination, as compared to action of DB alone; * p < 0.001 as compared to K1; ** p < 0.001 as compared to K2; *** p < 0.001 as compared to K3.

![Figure 5](image)
Using Q/DB combinations, increase in Q concentration at a stable concentration of DB was accompanied by a clear tendency for an increased calcein accumulation in RDB cells. The changes were statistically significant for combinations with Q6 and Q12 as compared to the action of DB alone (Figure 5). Taking into account increase in DB concentration at a stable concentration of Q we observed that it did not significantly affect calcein retention. Moreover, in combinations of Q12 with DB an increasing dose of DB was accompanied by a decreased fluorescence signal, in all probability due to a strong pro-apoptotic influence and a markedly reduced cell number (see Table 2; data about apoptosis not shown). Such phenomenon should be taken into account only if Q represented a substrate of P-gp and inhibition would take place by competition for the binding site. This was already suggested by some authors [28–30]. Nevertheless, our results related to cytotoxicity of Q to pancreatic carcinoma cells showed that Q cannot in this case represent a substrate of transporter proteins and the mechanism of its effects on P-gp transporter function is different. Several published reports indicate that Q represents an inhibitor of ATP-binding sites of P-gp [31–33]. It is also known that many inhibitors of ATP hydrolysis and factors affected \( \text{ABCB1} \) gene expression represent more effective modulators than P-gp substrates [10,26,32].

In our studies the exposure to Q was sufficiently long to allow not only its direct effect on the protein but also control of its expression at the level of DNA/mRNA. Many reports indicated that polyphenols, including Q, may affect expression of P-gp encoding gene [11,22,34]. In our studies the real-time PCR has been employed to establish whether Q affects expression of \( \text{ABCB1} \) gene. Relative analysis of the results permitted to compare effects of Q12 on cells in P and RDB lines. We find out that expression of \( \text{ABCB1} \) gene in RDB cells is 51-fold higher than in the P line. After administration of Q12 it was only 33-fold higher (Figure 6). In RDB cells Q12 decreased the expression of \( \text{ABCB1} \) by 35%. Additionally, in the case of P cells Q12 decreased expression of the gene by 67% (Figure 7).

**Figure 6.** Expression of \( \text{ABCB1} \) gene—Relative analysis (RQ) as compared to the sensitive cell line (denoted as 181P). Values of RQ: for 181P = 1, for 181P/12 = 0.3355, for 181RDB = 51.08, for 181RDB/12 = 33.34. Calibrator: P line.
Figure 7. Expression of ABCB1 gene—Relative analysis (RQ) as compared to the resistant cell line (denoted as 181RDB). Values of RQ: for 181P = 0.0195, for 181P/12 = 0.0065, for 181RDB = 1, for 181RDB/12 = 0.6526. Calibrator: RDB line.

The studies have focused on one of the most probable mechanisms of sensitizing the resistant cells to DB, through the effect of Q on P-gp expression and function. The flavonol was considered as a potential modulator of P-gp, affecting both the protein and the gene for it. Several reports indicated that Q might significantly help in overcoming MDR [1,2,21,22]. Some authors suggested that Q might also inhibit efflux of drugs from normal cells, e.g., in vascular endothelium, but only in high concentrations, most frequently exceeding 50 μM. On the other hand, lower doses may act reciprocally, intensifying elimination of toxic substances, which has a significant protective effect for normal tissues and organs [35]. Many data confirmed that Q and other polyphenols are potential P-gp expression and transport inhibitors which might sensitize resistant tumour cells to various drugs, including DB [27,34,36,37]. There are also available reports in which is described stimulation of the transport by some flavonoids, e.g., in cells of intestinal carcinoma resistant to DB [38,39]. Nevertheless, polyphenols do not act in the same way on all cells. Q exhibits pleiotropic properties depending on several conditions, e.g., type of tumour, redox status of cells, ATP concentration and/or applied time of Q and its concentration [40–42]. A 90% decrease in ATP-ase activity of P-gp was noted in MDR cells following application of 25 μM Q, while the same concentration was unable to affect ATP-ases of normal cells. Moreover, Q selectively influences kinases which participate in P-gp phosphorylation, e.g. protein kinase C, which manifests particularly high activity in MDR cells. Low Q concentrations might inhibit action of this type enzymes in tumour cells although no such effect has been noted yet in normal cells [21,42–46]. Q is also known to be capable of inhibiting the process of P-gp maturation in neoplastic cells such as molecule phosphorylation and its stabilization in the membrane [46]. Many data showed that Q not only exerts any inhibitory effect on transporters in normal cells and the important physiological barriers, but that it also protects healthy tissues from damage frequently accompanying action of a cytostatic drug [40,44,47–49]. The mutagenic effects on
normal cells described by some authors might be linked to administration of very high doses. Low concentrations of Q affect expression of genes which products protect healthy cells from damaging factors, such as free radicals, heavy metals or thermal shock [50–53].

Conclusions

Results of our studies confirmed that Q inhibits expression and function of P-gp in the RDB pancreatic carcinoma cell line. It is also effective in decreasing the expression of gene \textit{ABCB1} in both studied cell lines. Thus, Q may be considered as a potential sensitizer of neoplastic cells resistant to chemioterapeutics.

Experimental

Cell lines

The \textit{in vitro} studies were performed on cell lines of human pancreatic carcinoma sensitive (P) and resistant (RDB) to daunorubicin, EPP85-181P and EPP85-181RDB respectively. The cell lines were obtained from Institute of Pathology, University Hospital Charite in Berlin where they had been established by \textit{in vitro} exposure to daunorubicin (Farmitalia Carlo Erba, Freiburg, Germany). The cells were grown in Leibovitz's L-15 Medium (SIGMA, Germany) supplemented with 10% FBS, 1 mM L-glutamine, 80 IE/L insulin, 2.5 mg/L transferrin, 1.1 g/L NaHCO_3, 1 g/L glucose, 1% minimal essential vitamins (SIGMA, Germany). The cell culture of both cell lines followed the description of Lage et al. [54].

Calculation of resistance index for Q on the basis of cytotoxic tests

All proliferation tests were based on a colorimetric technique using sulphorhodamine B (SRB) dye, as described by Skehan et al. [55]. Substances used in the tests, quercetin (Q) and daunorubicin (DB), and the remaining reagents were purchased from SIGMA (Germany). The absorbance was read at the wavelength of 564 nm using a microplate-reader (ELX-800, BIO-TEK, USA). Concentrations of Q added 24h following starting the test: 1 µM, 2 µM, 3 µM, 6 µM, 12 µM, 25 µM and 50 µM. Q was dissolved in ethyl alcohol (concentration ≤ 0.12%), the adequate tests for the solvent were made before the further experiments. The absorbance in cultures with tested substances was read after 72 h after administration of the drugs. The cytotoxicity curves following 72 h (3 independent measurements) allowed to read out IC_{50} values and, then, Q resistance factor was calculated as follows: RF = IC_{50} for RDB/IC_{50} for P cells [36]. The cytotoxicity results permitted to select three concentrations of Q for further studies.

Immunocytochemical analysis of P-gp expression

Cells of the two cell lines were transferred to diagnostic slides at \(2 \times 10^4\) cells/mL (three repetitions), after 24 h the tested substances were added: Q: 3 µM (Q3), 6 µM (Q6), 12 µM (Q12); DB: K1 (0.043 µM), K2 (0.43 µM), the concentration corresponding to the so called therapeutic dose,
reflecting concentration of the cytostatic drug in patient’s blood two hours after its administration (for DB it amounted to 0.25 mg/mL), and K3 (4.3 µM); drug combinations: Q3/K1, Q3/K2, Q6/K1, Q6/K2, Q12/K1, Q12/K2; control (no drugs).

Following 72 h of incubation the cells were fixed in a cold (-20 °C) methanol-acetone (1:1) mixture for 15 min at the temperature of 4 °C and dried. Immunocytochemical detection of P-gp expression in cell membrane took advantage of LSAB+ System-HRP kit (Dako Cytomation, Denmark) and monoclonal P-gp-specific antibody, clone C-219 (Alexis Biochemicals, Germany). At the terminal stage of the immunocytochemical reaction DAB was used as a chromogen. Analysis of results was conducted under a light microscope (Olympus BX41, Japan). The percentage of cells was appraised which manifested P-gp expression among all cells in in five representative microscope fields (magnification 200×) for every well in a slide taking into account six wells and three independent repetitions.

Western blotting analysis of P-gp

Changes in P-gp expression in RDB line were examined after treatment with the Q12 concentration, as compared to the control. Additionally the amount of P-gp was examined in P line. Cells were cultured in flasks of 75 cm² surface. Q12 was added for 72 h, then the cells were trypsinized, centrifuged from trispin and medium, resuspended in PBS and scored in a Bürker haemocytometer. For each test 1.5–2 × 10⁷ exponentially grown cancer cell lines were washed in ice cold PBS and lysed on ice with RIPA buffer (50mM Tris-Cl pH 8.0, 150 mM NaCl, 0.1% SDS, 1% Igepal CA-630, Sigma, and 0.5% sodium deoxycholate) containing protease inhibitor cocktail (Sigma) and 0.5 mM PMSF. The cell debris were removed by centrifugation at 12 000 × g, 10 min. Protein concentration in resulting supernatant was measured using BCA method (Thermo-Pierce). Cell extracts were mixed with SDS sample buffer (250 mM TRIS pH 6.8, 40% glycerol, 20% (v/v) β-mercaptoethanol, 100 mM DTT, 0.33 mg/mL bromophenol blue, 8% SDS) and incubated on ice for 30 min to avoid membrane protein precipitation. Equal amounts of protein samples (20 µg per gel lane) were separated in 7% SDS-PAGE according to Laemmli [56], and blotted onto nitrocellulose membrane. Pgp expression was detected after incubation with Pgp-specific monoclonal antibody C219 (Alexis Biochemicals) using the chemiluminescence HRP detection substrate (Bio-Rad), and visualized with Chemi-Doc XRS Molecular Imager (Bio-Rad). To ensure equal protein loading blots were stripped and reprobed with mouse monoclonals to β-actin (ab8224, Abcam). Optical density measurements of the protein bands in immunoblots were performed with the QuantityOne software (Bio-Rad). Protein content in Pgp bands was normalized according to the actin content in each lane.

Transport function of P-gp

Alterations in transport function of P-gp under effect of Q were examined using calcein AM (CAM) assay. RDB cells were transferred to 96-well plates, at 800 cells per well. After 24 h wells with resistant cell lines were supplemented with Q and DB for the subsequent 72 h, at the following combinations (every in six copies, three repetitions): Q3, Q6, Q12, K1, K2, K3, Q3/K1, Q3/K2, Q3/K3, Q6/K1, Q6/K2, Q6/K3, Q12/K1, Q12/K2, Q12/K3. Some wells was left with no additions, as a control. P line served for the control for calculation of retention coefficient. Retention of CAM was
tested using Vybrant Multidrug Resistance Assay Kit (Molecular Probes, USA) according to the procedure given by the manufacturer [57]. The fluorescence was measured using a microspectrophotometer (Victor 2, USA) at 494/517 nm (Abs/Em). Values of fluorescence in P cell line (not treated with Q or DB) were used to calculate CAM retention coefficient for every applied drug combination in RDB line, according to the following formula: retention of CAM for RDB = [fluorescence of RDB cells treated with Q/fluorescence of P cells not treated with Q] × 100 [57].

**Examination of ABCB1 gene expression**

Changes in ABCB1 gene expression in P and RDB cell lines were examined for the Q12 concentration, as compared to the control. Cells were cultured in flasks of 25 cm² surface, two flasks per each cell line and, then, concentration Q12 was added to one of the flask pair leaving the other one as the control. Following 72 h incubation the cells were trypsinized, suspended in PBS, spun down (3×), resuspended in a defined volume of PBS and scored in a Bürker haemocytometer. Then, the cells were again suspended in PBS. RNA was isolated using the RNa-queue-4PCR kit (Ambion, UK) as described by the manufacturer. Reverse transcription was performed using High Capacity cDNA RT kit (Applied Biosystems, USA) and a thermal cycler (Thermal Cycler MJ Research PTC-200, Bio-Rad, USA). Examination of changes in expression of ABCB1 gene (Applied Biosystems, USA) was detected using real-time PCR. GAPDH (Applied Biosystems, USA) was applied as the normalizing gene, against which changes in the examined gene expression was compared. Real-time PCR was applied, using light-cycler’s 7900HT Fast Real-Time PCR System and SDS 2.3 software (Applied Biosystems, USA). Gene expression was analyzed using relative quantification RQ method and RQ Manager 1.2 software (Applied Biosystems, USA). RQ estimates difference at the level of gene expression against a calibrator (RQ of the calibrator = 1). P cell line not treated with Q and RDB cell line not treated with Q (as a comparison) were used as calibrators. The analysis was conducted employing the standard formula: RQ = 2^(-ΔΔCt), (where ΔΔCt = ΔCt for the sample - ΔCt for the calibrator). The graphs were made in the logarithmic scale using RQ Manager 1.2 software.

**Statistical analysis**

Statistical analysis of the results employed Student’s t-test (Mann-Whitney’s test) and SPSS 14.Pt software (SPSS Inc. USA). The results were regarded statistically significant at p < 0.01.

**Acknowledgements**

This work was supported by MNiSW Grant 2 PO5A 09830 (Poland) We would like to thank H. Lage (Charité University Hospital, Institute of Pathology, Berlin, Germany) for giving us permission to use EPP85-181P and EPP85-181RDB cell lines and Pawel Surowiak (Medical University Wrocław, Department of Histology and Embryology, Wrocław, Poland) for very valuable advices. We would also thank T. Gebarowski for technical assistance with the microspectrophotometer (Medical University Wrocław, Department of Basic Medical Sciences, Wrocław, Poland).
References

1. Gottesman, M.M.; Ling, V. The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research. FEBS Lett. 2006, 580, 998–1009.

2. Leslie, E.M.; Deeley, R.G.; Cole, S.P. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204, 216–237.

3. Shapiro, A.B.; Ling, V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur. J. Biochem. 1997, 250, 130–137.

4. Sharom, F.J.; Liu, R.; Romischki, Y.; Lu, P. Insights into the structure and substrate interactions of the P-glycoprotein multidrug transporter from spectroscopic studies. Biochim. Biophys. Acta 1999, 1461, 327–345.

5. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48–58.

6. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185–229.

7. Laurent, G.; Jaffrezou, J.P. Signaling pathways activated by daunorubicin. Blood 2001, 98, 913–924.

8. Szulawska, A.; Czyz, M. Molecular mechanisms of anthracyclines action. Postepy Hig. Med. Dosw. 2006, 60, 78–100.

9. Kim, Y.; Ma, A.G.; Kitta, K.; Fitch, S.N.; Ikeda, T.; Ihara, Y.; Simon, A.R.; Evans, T.; Suzuki Y.J. Anthracycline-induced suppression of GATA-4 transcription factor: Implication in the regulation of cardiac myocyte apoptosis. Mol. Pharmacol. 2003, 63, 368–377.

10. Varma, M.V.; Ashokraj, Y.; Dey, C.S.; Panchagnula, R. P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacol. Res. 2003, 48, 347–359.

11. Teodori, E.; Dei, S.; Scepecchi, S.; Gualtieri, F. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco 2002, 57, 385–415.

12. Formica, J.V.; Regelson, W. Review of the biology of Quercetin and related bioflavonoids. Food. Chem. Toxicol. 1995, 33, 1061–1080.

13. Erlund, I. Review of flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr. Res. 2004, 24, 551–874.

14. Nijveldt, R.J.; van Nood, E.; van Hoorn, D.E.; Boelens, P.G.; van Norren, K.; van Leeuwen, P.A. Flavonoids: A review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 2001, 74, 418–425.

15. Simic, A.; Manojlovic, D.; Segar, D.; Todorovic, M. Electrochemical behavior and antioxidant and prooxidant activity of natural phenolics. Molecules 2007, 12, 2327–2340.

16. Bast, A.; Haenen, G.R.; Bruyneel, A.M.; Van der Vijgh, W.J. Protection by flavonoids against anthracycline cardiotoxicity: From chemistry to clinical trials. Cardiovasc. Toxicol. 2007, 7, 154–159.
17. Le Good, J.A.; Ziegler, W.H.; Parekh, D.B.; Alessi, D.R.; Cohen, P.; Parker, P.J. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. *Science* **1998**, *281*, 2042–2045.

18. Nguyen, T.T.; Tran, E.; Nguyen, T.H.; Do, P.T.; Huynh, T.H.; Huynh, H. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. *Carcinogenesis* **2004**, *25*, 647–659.

19. Chen, D.; Dou, Q.P. Tea polyphenols and their roles in cancer prevention and chemotherapy. *Int. J. Mol. Sci.* **2008**, *9*, 1196–1206.

20. Yang, H.; Landis-Piwowar, K.R.; Chen, D.; Milacie, V.; Dou, Q.P. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment. *Curr. Protein Pept. Sci.* **2008**, *9*, 227–239.

21. Di Pietro, A.; Conseil, G.; Perez-Victoria, J.M.; Dayan, G.; Baubichon-Cortay, H.; Trompier, D.; Steinfels, E.; Jault, J.M.; de Wet, H.; Maitrejean, M.; Comte, G.; Boumendjel, A.; Mariotte, A.M.; Dumontet, C.; McIntosh, D.B.; Goffeau, A.; Castanys, S.; Gamarro, F.; Barron, D. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. *Cell. Mol. Life Sci.* **2002**, *59*, 307–322.

22. Kioka, N.; Hosokawa, N.; Komano, T.; Hirayoshi, K.; Nagata, K.; Ueda, K. Quercetin, a bioflavonoid, inhibits the increase of human multidrug resistance gene (MDR1) expression caused by arsenite. *FEBS Lett.* **1992**, *301*, 307–309.

23. Ozben, T. Mechanisms and strategies to overcome multiple drug resistance in cancer. *FEBS Lett.* **2006**, *580*, 2903–2909.

24. Bansal, T.; Awasthi, A.; Jaggi, M.; Khar, R.K.; Talegaonkar, S. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: Possible contribution of P-glycoprotein. *Life Sci.* **2008**, *83*, 250–259.

25. Choi, Y.J.; Jeong, Y.J.; Lee, Y.J.; Kwon, H.M.; Kang, Y.H. (−)-Epigallocatechin gallate and quercetin enhance survival signaling in response to oxidant-induced human endothelial apoptosis. *J. Nutr.* **2005**, *135*, 707–713.

26. van Erk, M.J.; Roepman, P.; van der Lende, T.R.; Stierum, R.H.; Aarts, J.M.; van Bladeren, P.J.; van Ommen, B. Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells *in vitro*. *Eur. J. Nutr.* **2005**, *44*, 143–156.

27. Borska, S.; Gebarowska, E.; Wysocka, T.; Drag-Zalesinska, M.; Zabel, M. The effects of quercetin vs cisplatin on proliferation and the apoptotic process in A549 and SW1271 cell lines in *in vitro* conditions. *Folia Morphol. (Warsz)* **2004**, *63*, 103–105.

28. Sarkadi, B.; Muller, M. Search for specific inhibitors of multidrug resistance in cancer. *Semin. Cancer Biol.* **1997**, *8*, 171–182.

29. Wang, Y.; Cao, J.; Zeng, S. Establishment of a P-glycoprotein substrate screening model and its preliminary application. *World J. Gastroenterol.* **2004**, *10*, 1365–1368.

30. Chieli, E.; Romiti, N.; Rodeiro-Guerra, I.; Garrido-Garrido, G. *In vitro* effects of Mangifera indica and polyphenols derived on ABCB1/P-glycoprotein activity. *Food Chem. Toxicol.* **2009**, DOI: 10.1016/j.fct.2009.07.017.
31. Hayeshi, R.; Masimirembwa, C.; Mukanganyama, S.; Ungell, A.L. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. *Eur. J. Pharm. Sci.* 2006, 29, 70–81.

32. Khantram, O.; Chaibangyen, W.; Limtrakul, P. Screening of flavonoids for their potential inhibitory effect on P-glycoprotein activity in human cervical carcinoma KB cells. *Chiang Mai Med. Bull.* 2004, 43, 45–56.

33. O’Leary, K.A.; de Pascual-Teresa, S.; Needs, P.W.; Bao, Y.P.; O’Brien, N.M.; Williamson, G. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. *Mutat. Res.* 2004, 551, 245–254.

34. Badhan, R.; Penny, J. In silico modelling of the interaction of flavonoids with human P-glycoprotein nucleotide-binding domain. *Eur. J. Med. Chem.* 2006, 41, 285–295.

35. Mitsunaga, Y.; Takanaga, H.; Matsuo, H.; Naito, M.; Tsuruo, T.; Ohtani, H.; Sawada, Y. Effect of bioflavonoids on vincristine transport across blood-brain barrier. *Eur. J. Pharmacol.* 2000, 395, 193–201.

36. Kothan, S.; Dechsupa, S.; Leger, G.; Moretti, J.L.; Vergote, J.; Mankhetkorn, S. Spontaneous mitochondrial membrane potential change during apoptotic induction by quercetin in K562 and K562/adr cells. *Can. J. Physiol. Pharmacol.* 2004, 82, 1084–1090.

37. Nabekura, T.; Kamiyama, S.; Kitagawa, S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. *Biochem. Biophys. Res. Commun.* 2005, 327, 866–870.

38. Critchfield, J.W.; Welsh, C.J.; Phang, J.M.; Yeh, G.C. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. *Biochem. Pharmacol.* 1994, 48, 1437–1445.

39. Morris, M.E.; Zhang, S. Flavonoid-drug interactions: Effects of flavonoids on ABC transporters. *Life Sci.* 2006, 78, 2116–2130.

40. O’Prey, J.; Brown, J.; Fleming, J.; Harrison, P.R. Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells. *Biochem. Pharmacol.* 2003, 66, 2075–2088.

41. Rosner, K.; Ropke, C.; Pless, V.; Skovgaard, G.L. Late type apoptosis and apoptosis free lethal effect of quercetin in human melanoma. *Biosci. Biotechnol. Biochem.* 2006, 70, 2169–2177.

42. Shapiro, A.B.; Ling, V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. *Biochem. Pharmacol.* 1997, 53, 587–596.

43. Shapiro, A.B.; Ling, V. Using purified P-glycoprotein to understand multidrug resistance. *J. Bioenerg. Biomembr.* 1995, 27, 7–13.

44. Son, Y.O.; Lee, K.Y.; Kook, S.H.; Lee, J.C.; Kim, J.G.; Jeon, Y.M.; Jang, Y.S. Selective effects of quercetin on the cell growth and antioxidant defense system in normal versus transformed mouse hepatic cell lines. *Eur. J. Pharmacol.* 2004, 502, 195–204.

45. Nagy, H.; Goda, K.; Fenyvesi, F.; Bacso, Z.; Szilasi, M.; Kappelmayer, J.; Lustyik, G.; Cianfriglia, M.; Szabo, G., Jr. Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. *Biochem. Biophys. Res. Commun.* 2004, 315, 942–949.

46. Germann, U.A. P-glycoprotein--a mediator of multidrug resistance in tumour cells. *Eur. J. Cancer* 1996, 32A, 927–944.
47. Miura, T.; Muraoka, S.; Fujimoto, Y. Inactivation of creatine kinase induced by quercetin with horseradish peroxidase and hydrogen peroxide. pro-oxidative and anti-oxidative actions of quercetin. *Food Chem. Toxicol.* **2003**, *41*, 759–765.

48. Moon, Y.J.; Wang, X.; Morris, M.E. Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. *Toxicol. In Vitro* **2006**, *20*, 187–210.

49. Ross, J.A.; Kasum, C.M. Dietary flavonoids: Bioavailability, metabolic effects, and safety. *Annu. Rev. Nutr.* **2002**, *22*, 19–34.

50. Dunnick, J.K.; Hailey, J.R. Toxicity and carcinogenicity studies of quercetin, a natural component of foods. *Fundam. Appl. Toxicol.* **1992**, *19*, 423–431.

51. Harwood, M.; Danielewska-Nikiel, B.; Borzelleca, J.F.; Flamm, G.W.; Williams, G.M.; Lines, T.C. A critical review of the data related to the safety of quercetin and lack of evidence of *in vivo* toxicity, including lack of genotoxic/carcinogenic properties. *Food Chem. Toxicol.* **2007**, *45*, 2179–2205.

52. Okamoto, T. Safety of quercetin for clinical application (Review). *Int. J. Mol. Med.* **2005**, *16*, 275–278.

53. Gupta, C.; Vikram, A.; Tripathi, D.N.; Ramarao, P.; Jena, G.B. Antioxidant and antimutagenic effect of quercetin against DEN induced hepatotoxicity in rat. *Phytother. Res.* **2009**, DOI: 10.1002/ptr.2883

54. Lage, H.; Jordan, A.; Scholz, R.; Dietel, M. Thermosensitivity of multidrug-resistant human gastric and pancreatic carcinoma cells. *Int. J. Hyperthermia* **2000**, *16*, 291–303.

55. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. *J. Natl. Cancer Inst.* **1990**, *82*, 1107–1112.

56. Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **1970**, *227*, 680–685.

57. Tiberghien, F.; Loo, F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. *Anticancer Drugs* **1996**, *7*, 568–578.

*Sample Availability:* Samples of the compounds are available from the authors.

© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).